Cargando…
T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY
Autores principales: | Cingolani, A., Felice, C., Lombardi, G., Onidi, F.M., Checchin, D., Colucci, R., Grossi, L., Ferronato, A., Rocchi, C., Ascolani, M., Binaghi, L., Dore, M.F., Fanini, L., Bulajic, M., Mocci, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065934/ http://dx.doi.org/10.1016/S1590-8658(22)00427-3 |
Ejemplares similares
-
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021) -
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
por: Velayudhan, Jyoti, et al.
Publicado: (2016) -
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
por: Liu, Jennifer, et al.
Publicado: (2016) -
A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
por: Markus, Richard, et al.
Publicado: (2019) -
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)